Foqus Technologies, a pioneer that leverages both Quantum technologies and AI to enhance medical imaging, announces that its first AI-powered MRI reconstruction software, DeepFoqus-Accelerate, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Built on Foqus’s proprietary AI technology, DeepFoqus integrates with existing MRI systems and workflows to reduce scan times by 75% while maintaining image quality comparable to standard non-accelerated scans. This breakthrough will transform medical imaging and significantly empower healthcare providers to improve MRI efficiency, enhance the patient experience, and support better clinical outcomes.
This FDA clearance marks a key milestone for Foqus to bring DeepFoqus to the market. With regulatory approval now in place, we are excited to gear up for the official launch of DeepFoqus-Accelerate and begin delivering faster and cost-effective imaging solutions to healthcare providers across the U.S.
